Lopinavir (ABT-378): Potent HIV Protease Inhibitor for Antiviral Research

Executive Summary: Lopinavir (ABT-378) is a ritonavir analog and a highly potent inhibitor of HIV protease, exhibiting inhibition constants (K_i) between 1.3 and 3.6 pM against both wild-type and mutant enzymes (APExBIO). It maintains efficacy against Val82 mutant HIV strains, with an EC₅₀ below 0.06 μM in cell-based assays. Lopinavir demonstrates approximately 10-fold greater antiviral potency than ritonavir in the presence of human serum proteins (APExBIO). Pharmacokinetic studies show that oral administration at 10 mg/kg yields a Cmax of 0.8 μg/mL and 25% bioavailability, with co-administration of ritonavir increasing exposure 14-fold. Lopinavir also displays cross-pathogen antiviral activity, including inhibition of MERS-CoV replication in the low micromolar range (de Wilde et al., 2014).

Biological Rationale

Lopinavir was developed as a next-generation HIV protease inhibitor to overcome resistance and serum binding limitations observed with earlier drugs such as ritonavir. The HIV protease enzyme is essential for viral maturation, cleaving the Gag-Pol polyprotein into functional viral proteins. Inhibition of this protease halts viral replication and particle assembly (Lopinavir: Potent HIV Protease Inhibitor for Antiviral Research). Lopinavir's molecular structure (C₃₇H₄₈N₄O₅, MW 628.81 g/mol) was optimized to reduce interaction with the Val82 residue, a frequent mutation site conferring drug resistance (Mechanistic Precision in HIV Protease Inhibition). This design enables robust activity against both wild-type and mutant HIV strains.

Mechanism of Action of Lopinavir

Lopinavir is a competitive inhibitor of the HIV-1 protease enzyme. It binds to the active site, blocking substrate access and preventing cleavage of viral polyproteins. This action leads to the formation of immature, non-infectious viral particles. Lopinavir's reduced affinity for serum binding proteins ensures higher free drug concentrations in vivo compared to ritonavir. In cell-based assays, Lopinavir is effective at concentrations as low as 4–52 nM (APExBIO). The drug's mechanism directly targets the protease enzymatic pathway, providing a critical tool for HIV protease inhibition assays and mechanistic research (Mechanistic Mastery and Strategic Frontiers—this article extends mechanistic insight by providing resistance data and cross-pathogen efficacy).

Evidence & Benchmarks

• Lopinavir inhibits wild-type and mutant HIV proteases with K_i values of 1.3–3.6 pM (APExBIO, Product Dossier).
• The EC₅₀ against Val82 mutant HIV strains is <0.06 μM, indicating high potency in resistant backgrounds (APExBIO).
• Lopinavir demonstrates 10-fold higher efficacy in human serum than ritonavir, addressing serum protein binding limitations (APExBIO).
• In animal models, 10 mg/kg oral Lopinavir yields Cmax 0.8 μg/mL and 25% bioavailability; plasma levels drop below quantitation by 6 hours (APExBIO).
• Co-administration with ritonavir increases Lopinavir exposure 14-fold, facilitating therapeutic plasma levels (APExBIO).
• Lopinavir inhibits MERS-CoV replication with EC₅₀ of 3–8 μM in cell culture (de Wilde et al., 2014).
• Demonstrated activity against SARS-CoV and HCoV-229E, suggesting cross-pathogen potential (de Wilde et al., 2014).
• Significantly less resistance observed in multi-mutant HIV strains versus ritonavir (Proven Solutions for HIV Protease Assays—this article updates with new resistance data and integration tips).

Applications, Limits & Misconceptions

Lopinavir is widely used for:

• HIV protease inhibition assays and mechanistic studies.
• High-throughput screening in antiretroviral therapy development.
• Resistance profiling in HIV drug resistance studies.
• Exploratory cross-pathogen antiviral research (e.g., coronaviruses in cell culture).

Its robust efficacy in the presence of serum proteins and against mutant HIV strains make it a preferred standard for comparative studies.

Common Pitfalls or Misconceptions

• Not effective as monotherapy for advanced or multi-drug resistant HIV in vivo: Lopinavir is typically used in combination with ritonavir to ensure sufficient plasma exposure; monotherapy may result in subtherapeutic levels (APExBIO).
• Limited solubility in aqueous buffers: The compound is insoluble in water; use DMSO or ethanol for stock solutions (≥31.45 mg/mL in DMSO, ≥48.3 mg/mL in ethanol).
• Not a cure for COVID-19 or other coronavirus infections: While in vitro activity against MERS-CoV and SARS-CoV has been demonstrated, clinical efficacy in coronavirus disease is not established (de Wilde et al., 2014).
• Short plasma half-life without ritonavir boosting: Plasma levels fall below quantification within 6 hours post-dose unless co-administered with ritonavir (APExBIO).
• Activity may not extrapolate to all proteases: Lopinavir is selective for HIV protease and shows limited or no activity against unrelated protease families.

Workflow Integration & Parameters

Lopinavir (SKU A8204) from APExBIO can be integrated into HIV protease inhibition assays and antiviral research workflows as follows:

• Preparation: Dissolve in DMSO or ethanol to prepare concentrated stock solutions. Avoid aqueous buffers due to insolubility.
• Storage: Store solid and solutions at -20°C; solutions should be freshly prepared for optimal activity.
• Assay Use: Effective in cell-based assays at 4–52 nM. For resistance studies, test against both wild-type and mutant HIV protease variants.
• PK/PD Studies: For animal experiments, oral dosing at 10 mg/kg is standard for initial pharmacokinetic assessments.
• Combination Therapy: Co-administration with ritonavir is recommended to enhance plasma exposure and prolong half-life.

For comprehensive protocol optimization and troubleshooting, see Lopinavir (SKU A8204): Proven Solutions for HIV Protease Assays; this article extends those best practices with updated benchmarks and advanced resistance insights.

Conclusion & Outlook

Lopinavir remains a foundational reagent for HIV protease inhibition, antiretroviral therapy development, and drug resistance studies. Its robust efficacy, favorable pharmacokinetics, and resistance-resilient design—especially as provided by APExBIO—secure its status as a standard for mechanistic and translational antiviral research. While its in vitro cross-pathogen activity is of interest, further validation is needed before broader clinical application. For additional mechanistic insights and strategic guidance, refer to Lopinavir (ABT-378): Mechanistic Mastery and Strategic Frontiers; this article updates with recent resistance and cross-pathogen evidence.

For product details, protocols, and ordering, visit the Lopinavir A8204 product page.